ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C0225668 | A rounded, club-shaped, nonciliated cell found in between ciliated cells in the epithelium of respiratory and terminal bronchioles. It has a secretory function. | Clara cell|Bronchiolar non-ciliated cell|Nonciliated Bronchiolar Epithelial Cell|Club Cell|Clara cell of bronchiole|clara cell|Clara cell of bronchiole (cell)|cells clara | Clara cell |
C0225700 | Cuboidal epithelial cells that line the PULMONARY ALVEOLI and produce and secret PULMONARY SURFACTANTS. | Type II alveolar epithelial cell|Alveolar type II cell|Pneumocyte, Type 2|alveolar type II cell|Alveolar Cell Type II|alveolar cells ii type|Pneumocyte, type 2 (cell)|Type 2 pneumocyte|Type II alveolar cell|Pneumocyte, Type-II|Type-II alveolar cell|type ii alveolar cell|Pneumocytes, Type 2|Pneumocytes, Type-II|Great alveolar cell|Alveolar cell type II|Type II Pneumocyte|Type 2 Pneumocyte|Type II Pneumocytes|Type-II Pneumocyte|Cuboidal type II cell|Pneumocyte, type 2|Type 2 Pneumocytes|Granular pneumocyte | Type-II Pneumocytes |
C1512116 | A molecular genetic abnormality indicating the presence of multiple copies of the EGFR gene. | Epidermal Growth Factor Receptor Gene Activation|EGFR Gene Amplification|c-erbB1 Gene Amplification|Epidermal Growth Factor Receptor Gene Amplification|EGFR Gene Activation|HER1 Gene Amplification|EGFR Amplification | EGFR Gene Amplification |
C0241956 | null | JUVENILE POLYARTHRITIS|juvenile polyarthritis|polyarthritis juvenile | Juvenile polyarthritis |
C0241956 | null | JUVENILE POLYARTHRITIS|juvenile polyarthritis|polyarthritis juvenile | Juvenile polyarthritis |
C1327811 | null | chromosome 9p | chromosome 9p |
C0028945 | A relatively slow-growing glioma that is derived from oligodendrocytes and tends to occur in the cerebral hemispheres, thalamus, or lateral ventricle. They may present at any age, but are most frequent in the third to fifth decades, with an earlier incidence peak in the first decade. Histologically, these tumors are encapsulated, relatively avascular, and tend to form cysts and microcalcifications. Neoplastic cells tend to have small round nuclei surrounded by unstained nuclei. The tumors may vary from well-differentiated to highly anaplastic forms. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2052; Adams et al., Principles of Neurology, 6th ed, p655) | Oligodendroglioma, Not Otherwise Specified|Oligodendrogliomas|Oligodendroglioma, no ICD-O subtype|Oligodendroglioma|Oligodendroglioma, no International Classification of Diseases for Oncology subtype (morphologic abnormality)|Oligodendroglioma, NOS|Oligodendroglioma, no International Classification of Diseases for Oncology subtype | oligodendroglioma |
C0920269 | The occurrence of highly polymorphic mono- and dinucleotide MICROSATELLITE REPEATS in somatic cells. It is a form of genome instability associated with defects in DNA MISMATCH REPAIR. | MSI Positive|Microsatellite Instability|microsatellite instability|Microsatellite Instability Present|Microsatellite Instability Positive|instability microsatellite|MSI Present|MSI|Instability, Microsatellite | Microsatellite Instability |
C1332838 | A gene proposed to have a primary role in a disease, based upon its known function in other organisms or model systems or based upon its physical proximity to markers linked to a genetic disease. | Target Gene|Candidate Genes|Candidate Gene|Candidate Disease Gene | Candidate Disease Gene |
C0267809 | Cirrhosis in which no causative agent can be identified. | cirrhosis cryptogenic|Cryptogenic cirrhosis (disorder)|CIRRHOSIS, CRYPTOGENIC|Cirrhosis, cryptogenic|Cryptogenic cirrhosis|cryptogenic cirrhosis|Cryptogenic Cirrhosis | Cirrhosis, Cryptogenic |
C1290916 | Imaging results obtained through a radiology procedure. | RADIOLOGIC FINDING|Radiologic finding (finding)|Radiologic Finding | Radiologic finding |
C0333575 | null | Fatty infiltration (morphologic abnormality)|Fatty infiltration|fatty infiltration|Infiltration, fatty | Fatty infiltration |
C0021829 | null | Bypasses, Intestinal|intestinal bypass|intestine bypass|bypass intestine|Intestinal Bypasses|Bypass, Intestinal | Intestinal Bypass |
C1456587 | Surgery performed in morbidly obese patients to help promote weight loss. The procedure aims at the reduction of the stomach size and it is usually achieved either with the implantation of a medical device or the removal of part of the stomach. | Bariatric surgery|Bariatric Surgery|Surgical Procedure, Bariatric|Procedure, Bariatric Surgical|Gastrointestinal Bariatric Surgery|Surgeries, Bariatric|Metabolic Surgery|Bariatric Surgeries|weight loss surgery|Weight Loss Surgery|Surgical Procedures, Bariatric|Surgery, Bariatric|Surgery, Metabolic|Bariatric Surgical Procedures|Procedures, Bariatric Surgical|bariatric surgery|Surgeries, Metabolic|Metabolic Surgeries|Bariatric Surgical Procedure | Bariatric Surgery |
C0033522 | Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. | Prospective Study|Study, Prospective|prospective studies|prospective study|Studies, Prospective|prospective longitudinal study|Prospective Studies|projective study | Prospective Studies |
C0376636 | A broad approach to appropriate coordination of the entire disease treatment process that often involves shifting away from more expensive inpatient and acute care to areas such as preventive medicine, patient counseling and education, and outpatient care. This concept includes implications of appropriate versus inappropriate therapy on the overall cost and clinical outcome of a particular disease. (From Hosp Pharm 1995 Jul;30(7):596) | Managements, Disease|management|Management, Disease|Disease management|Disease Managements|Disease Management|disease management | Disease Management |
C0428321 | null | Liver enzyme levels|enzymes hepatic|hepatic enzyme|liver enzyme levels|enzymes levels liver|enzymes liver measurements|enzyme level liver|Measurement of liver enzyme (procedure)|enzymes level liver|liver enzyme test|enzyme levels liver|Measurement of liver enzyme|liver enzyme levels test|liver enzyme level | Measurement of liver enzyme |
C0037265 | Extended care facilities which provide skilled nursing care or rehabilitation services for inpatients on a daily basis. | skilled nursing facility|Nursing Facility, Skilled|Skilled Nursing Facilities|skilled nursing facilities|Nursing & Custodial Care Facilities; Skilled Nursing Facility|Nursing Home|Care Facility, Extended|Skilled care facility|Extended care facility (environment)|Skilled Nursing Facility|Skilled nursing facility|Extended care units|Skilled nursing facility (environment)|care extended facilities|extended care facilities|care facilities skilled|Care Facilities, Extended|Extended care facility|Nursing Facilities, Skilled|facilities nursing skilled|extended care facility|Extended Care Facility|Extended Care Facilities|Skilled nursing facility, NOS|Facilities, Extended Care|Facilities, Skilled Nursing|Facility, Extended Care|Facility, Skilled Nursing | skilled nursing facility |
C1254359 | null | null | Physiologic Function |
C1417931 | null | OCRL|OCRL1|OCRL GENE|OCRL gene|OCRL inositol polyphosphate-5-phosphatase | OCRL gene |
C1417931 | null | OCRL|OCRL1|OCRL GENE|OCRL gene|OCRL inositol polyphosphate-5-phosphatase | OCRL gene |
C0055856 | A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation. | 6-O-Methylerythromycin|CLA|CLARITHROMYCIN|Claritromicina|Clarithromycin-containing product|Clarithromycine|Product containing clarithromycin (medicinal product)|CLARITH|Clarithromycinum|6-O-methylerythromycin|Erythromycin, 6-O-methyl-|Clarithromycin (substance)|Clarithromycina|Clarithromycin|clarithromycin|6-O-methyl erythromycin | clarithromycin |
C0180321 | A densitometer is a device used to measure the transmission of light through an indicator in a sample of blood. | DENSITOMETER|densitometers|densitometer | Densitometer |
C0598051 | null | null | vascular bed |
C0023348 | A chronic communicable infection which is a principal or polar form of LEPROSY. This disorder is caused by MYCOBACTERIUM LEPRAE and produces diffuse granulomatous skin lesions in the form of nodules, macules, or papules. The peripheral nerves are involved symmetrically and neural sequelae occur in the advanced stage. | Leprosies, Lepromatous|LL - Full lepromatous leprosy|Lepromatous Leprosy|Lepromatous leprosy [type L]|Type L leprosy|Type LL leprosy|LEPROMATOUS LEPROSY|Lepromatous Leprosies|Lepromatous leprosy (disorder)|HANSEN DISEASE, MALIGNANT FORM|Full lepromatous leprosy|Lepromatous leprosy|LEPROSY, LEPROMATOUS | Leprosy, Lepromatous |
C1515974 | Named locations of or within the body. | Anatomic Sites|Anatomic Site|Site|Location|Anatomic Location|Topographic Site | Anatomic Site |
C0008059 | A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. | Children (0-21)|0-11 years old|CHILD|Children|children|Childhood age person (person)|Child Youth|Child|Child (person)|child|Child, NOS|Childhood age person | Child |
C0229654 | Nodular structures composed of lymphocytes. In the absence of immune stimulation, they ae called primary follicles and are composed of small B-lymphocytes. With antigenic stimulation the B-lymphocytes replicate and differentiate, to give rise to secondary follicles which are composed of germinal centers and are surrounded by mantle zones. | Lymphoid nodule|lymphoid nodule|Lymphoid follicle|Lymph node follicle|Nodular lymphoid tissue|Lymphoid nodule (body structure)|Lymphoid nodule of bone marrow|Marrow lymphoid nodule|Lymphoid Follicle|lymphoid follicle | Lymphoid nodule |
C0010646 | A homologous group of endogenous CYSTEINE PROTEINASE INHIBITORS. The cystatins inhibit most CYSTEINE ENDOPEPTIDASES such as PAPAIN, and other peptidases which have a sulfhydryl group at the active site. | cystatin|Cystatin Superfamily|Cystatins | Cystatins |
C1519547 | Nodules of lymphoid tissue located on either side of the back of the nasal canal and throat. | Tonsillar Tissue | Tonsillar Tissue |
C0004591 | A species of bacteria whose spores vary from round to elongate. It is a common soil saprophyte. | bacillus megatherium|Bacillus megatherium|Bacillus megaterium|Bacillus megaterium (organism)|bacillus megaterium|Bacillus fructosus|BACILLUS MEGATERIUM | Bacillus megaterium |
C0010646 | A homologous group of endogenous CYSTEINE PROTEINASE INHIBITORS. The cystatins inhibit most CYSTEINE ENDOPEPTIDASES such as PAPAIN, and other peptidases which have a sulfhydryl group at the active site. | cystatin|Cystatin Superfamily|Cystatins | Cystatins |
C0935576 | null | treatment guidelines | treatment guideline |
C0679782 | null | prophylactics use|condom use|prophylactic use|condoms use|Condom use | condom use |
C1145759 | An aza-dipeptide analogue with a bis-aryl substituent on the (hydroxethyl)hydrazine moiety with activity against both wild type and mutant forms of HIV protease. Atazanavir does not elevate serum lipids, a common problem with other protease inhibitors. | atazanavir|Atazanavirum|Atazanavir|Atazanavir (substance)|ATZ|ATAZANAVIR|Product containing atazanavir (medicinal product)|3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-2,5,6,10,13-pentaazatetradecanedioic acid dimethyl ester|Atazanavir-containing product | atazanavir |
C0003618 | Natural recurring desire for food. Alterations may be induced by APPETITE DEPRESSANTS or APPETITE STIMULANTS. | desire for food|Appetite|appetite|appetites|Food appetite, NOS|Food appetite, function (observable entity)|Desire for food|Appetites|Food appetite|Food appetite, function | Desire for food |
C0040135 | Natural hormones secreted by the THYROID GLAND, such as THYROXINE, and their synthetic analogs. | Thyroid Agent|Thyroid hormones|Thyroid Hormone|Thyroid Gland Hormone|THYROID HORMONES|thyroid hormone|thyroid hormones|Thyroid hormone|Thyroid hormone, NOS|Thyroid hormone (substance)|Hormones, Thyroid|Thyroid Hormones | Thyroid Hormones |
C0085281 | The observable, measurable, and often pathological activity of an organism that portrays its inability to overcome a habit resulting in an insatiable craving for a substance or for performing certain acts. The addictive behavior includes the emotional and physical overdependence on the object of habit in increasing amount or frequency. | addictive behavior|Behavior, Addictive|ADDICTION|DEPENDENCE ADDICTIVE|Addiction (finding)|addiction|addictive behaviors|Addictive Behaviors|addictions|Behaviors, Addictive|Addiction, NOS|Addictive behavior|Addiction|Addictive Behavior | Addictive Behavior |
C0440731 | null | Foetal brain|Fetal brain (substance)|Fetal brain|fetal brain|brain fetal | Fetal brain |
C0026936 | Infections with species of the genus MYCOPLASMA. | mycoplasmosis|Mycoplasma infection (disorder)|Infection by PPLO, NOS|Disease caused by Mycoplasma, NOS|mycoplasma|Mycoplasmosis, NOS|Mycoplasma Infection|mycoplasma infections|Mycoplasmosis|mycoplasma infection|Disease caused by mycoplasma|Infections, Mycoplasma|Mycoplasma Infections|Infection, Mycoplasma|Mycoplasma infection|MYCOPLASMA INFECTIONS|Infection by Mycoplasma, NOS | Mycoplasma Infections |
C1261287 | The condition of an anatomical structure's being constricted beyond normal dimensions. | stenosis|Constriction|constriction|Stricture|Pathologic Constriction|stenose|Stenosis (morphologic abnormality)|Stricture (morphologic abnormality)|Constriction, NOS|stenosi|stenoses|Stenosis, NOS|Stenoses|abnormal narrowing of a duct or passage|Constriction, Pathological|stricture|Strictures|Pathological Constriction|Stricture, NOS|Stenosis|Constriction, Pathologic|Constrictions, Pathologic|strictures|abnormal narrowing|Pathologic Constrictions | Stenosis |
C0027122 | A disease characterized by bony deposits or the ossification of muscle tissue. | muscle calcification|Muscular ossification, NOS|Ossifying interstitial myositis|muscular calcification|myositis ossifican|Muscular ossification|Muscle calcification and ossification|Myisitis ossificans|ossificans myositis|Muscular ossification (disorder)|Muscle ossification|Myositis Ossificans|myositis ossificans|Myositis ossificans | Myositis Ossificans |
C1269041 | null | Entire abdominal wall|Entire AW - Abdominal wall|Entire abdominal wall (body structure) | Entire abdominal wall |
C1334234 | A lymphangioma arising from the organs of the abdominal cavity. | null | Intra-Abdominal Lymphangioma |
C0041667 | null | Excessive body weight loss|Low weight|patient underweight|weight low|LOW WEIGHT|UNDERWEIGHT|WEIGHT LOSS, SEVERE|Underweight (finding)|Low body weight|Underweight|underweight|severe weight loss|low weight|Patient underweight|weight loss severe|Body weight loss, excessive | Underweight |
C0029713 | null | Other preterm infants|Other preterm infants, unspecified|Other preterm infants, unspecified weight | Other preterm infants, unspecified [weight] |
C0268731 | Chronic degenerative changes in the glomeruli characterized by loss of cellularity of glomerular capillary tufts and acellular deposition of immunoglobulins. | Renal glomerular syndrome, NOS|Glomerular disease (disorder)|Renal glomerular disease, NOS|glomerular diseases|Glomerulopathy|Renal glomerular disorder, NOS|Renal glomerular disease or syndrome|Diseased glomeruli|GLOMERULAR|Glomerular disease|glomerulonephropathy|GLOMERULOPATHY|RENAL GLOMERULAR DISEASES|glomerular disease|Glomerulonephropathy|renal glomerular disease|Renal Glomerular Diseases and Syndromes | Renal glomerular disease |
C1333579 | This gene is involved in signal transduction. | FRS2beta|fibroblast growth factor receptor substrate 3|SUC1-ASSOCIATED NEUROTROPHIC FACTOR TARGET 2|FRS2-BETA|FRS2B|FRS3 gene|Fibroblast Growth Factor Receptor Substrate 3 Gene|FGFR SUBSTRATE 3|FRS3 Gene|SNT-2|FRS3|FIBROBLAST GROWTH FACTOR RECEPTOR SUBSTRATE 3|SNT2 | FRS3 gene |
C1333579 | This gene is involved in signal transduction. | FRS2beta|fibroblast growth factor receptor substrate 3|SUC1-ASSOCIATED NEUROTROPHIC FACTOR TARGET 2|FRS2-BETA|FRS2B|FRS3 gene|Fibroblast Growth Factor Receptor Substrate 3 Gene|FGFR SUBSTRATE 3|FRS3 Gene|SNT-2|FRS3|FIBROBLAST GROWTH FACTOR RECEPTOR SUBSTRATE 3|SNT2 | FRS3 gene |
C1333579 | This gene is involved in signal transduction. | FRS2beta|fibroblast growth factor receptor substrate 3|SUC1-ASSOCIATED NEUROTROPHIC FACTOR TARGET 2|FRS2-BETA|FRS2B|FRS3 gene|Fibroblast Growth Factor Receptor Substrate 3 Gene|FGFR SUBSTRATE 3|FRS3 Gene|SNT-2|FRS3|FIBROBLAST GROWTH FACTOR RECEPTOR SUBSTRATE 3|SNT2 | FRS3 gene |
C0205102 | Happening or arising or located within some limits, or especially, within some surface. | internal|Internal (qualifier value)|Internally|Inner|inside|Inside|Internal|insides|intrinsic|Intramural|inner|INNER|Intrinsic|intrinsics | Internal |
C0674323 | null | 6-MeSC6 isothiocyanate | 6-methylsulfinylhexyl isothiocyanate |
C0674323 | null | 6-MeSC6 isothiocyanate | 6-methylsulfinylhexyl isothiocyanate |
C0230764 | The lipid bilayer surrounding any of the compartments of the Golgi apparatus. [GOC:mah] | Golgi membrane|Golgi membrane (cell structure) | Golgi membrane |
C0084569 | null | slit protein, Drosophila|wdh protein, Drosophila|dSlit protein, Drosophila | sli protein, Drosophila |
C1415361 | This gene plays a role in the metabolism of GTP. It is also involved in nitric oxide-mediated signal transduction in the cardiovascular system. | GUCY1B2|Guanylate Cyclase 1, Soluble, Beta 2 Gene|guanylate cyclase 1 soluble subunit beta 2 (pseudogene)|GUANYLATE CYCLASE 1, SOLUBLE, BETA-2|GUCY1B2 Gene|GC-SB2|GCS-BETA-2|GUCY1B2 gene|GUANYLATE CYCLASE, SOLUBLE, BETA-2 | GUCY1B2 gene |
C1415361 | This gene plays a role in the metabolism of GTP. It is also involved in nitric oxide-mediated signal transduction in the cardiovascular system. | GUCY1B2|Guanylate Cyclase 1, Soluble, Beta 2 Gene|guanylate cyclase 1 soluble subunit beta 2 (pseudogene)|GUANYLATE CYCLASE 1, SOLUBLE, BETA-2|GUCY1B2 Gene|GC-SB2|GCS-BETA-2|GUCY1B2 gene|GUANYLATE CYCLASE, SOLUBLE, BETA-2 | GUCY1B2 gene |
C0963377 | The prototypical and most well-studied member of the semaphorin family. Semaphorin-3A is an axon-repulsive guidance cue for migrating neurons in the developing nervous system. It has so far been found only in vertebrates, and binds to NEUROPILIN-1/plexin complex receptors on growth cones. Like other class 3 semaphorins, it is a secreted protein. | Semaphorin-3A|Collapsin|Collapsing Factor|Collapsin-1|Sem D|Semaphorin 3A|Sema3A|Collapsin 1|Semaphorin D | Semaphorin-3A |
C0030899 | A METHYLXANTHINE derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production. | Pentoxifyllinum|Pentoxifyllin|Product containing pentoxifylline (medicinal product)|1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-|Pentoxifilina|PTX|Oxpentifylline|oxpentifylline|Pentoxifylline (substance)|Pentoxifylline-containing product|3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione|pentoxyphylline|PENTOXIFYLLINE|pentoxifylline|Pentoxifylline|Pentoxyphylline | pentoxifylline |
C0001925 | The presence of albumin in the urine, an indicator of KIDNEY DISEASES. | Albuminurias|albuminuria|Albuminuria|ALBUMINURIA|Albuminuria (finding)|Albuminuria, NOS | Albuminuria |
C0988533 | null | null | Pentoxifylline 400 MG |
C0052335 | null | L-arginine, methyl ester | arginine methyl ester |
C1177422 | null | benzocaine 20 % / triclosan 0.13 % Topical Spray|BENZOCAINE 200 mg in 1 mL / TRICLOSAN 1.3 mg in 1 mL TOPICAL SPRAY [First Degree Burn]|BENZOCAINE 20 g in 100 g / TRICLOSAN 130 mg in 100 g TOPICAL AEROSOL, SPRAY [Good Neighbor Pharmacy First Aid]|BENZOCAINE 17 g in 85 g / TRICLOSAN 0.11 g in 85 g TOPICAL AEROSOL, SPRAY [Benzocaine and Triclosan] | Benzocaine 200 MG/ML / Triclosan 1.3 MG/ML Topical Spray |
C1177422 | null | benzocaine 20 % / triclosan 0.13 % Topical Spray|BENZOCAINE 200 mg in 1 mL / TRICLOSAN 1.3 mg in 1 mL TOPICAL SPRAY [First Degree Burn]|BENZOCAINE 20 g in 100 g / TRICLOSAN 130 mg in 100 g TOPICAL AEROSOL, SPRAY [Good Neighbor Pharmacy First Aid]|BENZOCAINE 17 g in 85 g / TRICLOSAN 0.11 g in 85 g TOPICAL AEROSOL, SPRAY [Benzocaine and Triclosan] | Benzocaine 200 MG/ML / Triclosan 1.3 MG/ML Topical Spray |
C1155633 | The cell cycle process in which the sister chromatids of a replicated chromosome become tethered to each other. [GOC:jh, GOC:mah, ISBN:0815316194] | coheson-mediated DNA tethering | sister chromatid cohesion |
C0025186 | A type of CELL NUCLEUS division, occurring during maturation of the GERM CELLS. Two successive cell nucleus divisions following a single chromosome duplication (S PHASE) result in daughter cells with half the number of CHROMOSOMES as the parent cells. | Meiosis, function (observable entity)|Meiosis, function|Meioses|crossing over (meiosis)|meiosis|Meiosis | Meiosis |
C0907709 | null | cohesin | cohesins |
C0303695 | null | Argon isotope|Argon isotope (substance) | Argon isotope |
C0008139 | Order of mammals whose members are adapted for flight. It includes bats, flying foxes, and fruit bats. | Chiroptera species|Order Chiroptera|Bats|bats|Order Chiroptera (organism)|Bat - animal|Order Chiroptera - bat|ORDER CHIROPTERA - BATS|Bat|bat|Chiroptera|Bat, NOS | Chiroptera |
C1291208 | intermediate in the Krebs' cycle; also produced from glutamate in amino group transfer reactions and by oxidative deamination. | 2-oxoglutarate|Alpha ketoglutarate (substance)|alpha ketoglutarate|alpha Oxoglutarate|Alpha ketoglutarate|2-ketoglutarate|2-Oxoglutarate|alpha-Oxoglutarate|2 Ketoglutarate|Alpha Ketoglutarate|2 Oxoglutarate|alpha Ketoglutarate|2-Ketoglutarate|Alpha-Ketoglutarate|alpha-ketoglutarate | alpha-Ketoglutarate |
C0537536 | null | null | syringomycin E |
C0024076 | an albumin with a heterocyclic prosthetic group found in fireflies and other animals which, in the presence of ATP and the enzyme luciferase, becomes luminescent. | null | luciferin |
C0301641 | null | Macromolecular alteration|changes conformational|Macromolecular alteration (finding)|Macromolecular alteration, NOS|Conformational change|Macromolecular Alteration|Macromolecular Alterations|Conformational change, NOS|conformational change | Macromolecular alteration |
C0036589 | Administration of a drug or chemical by the individual under the direction of a physician. It includes administration clinically or experimentally, by human or animal. | Administration, Self|self-administration of drugs|self administration|Self-administration of medication (procedure)|Self-administration of medication|Administrations, Self|Self Administrations | Self Administration |
C0072892 | A dopamine D2/D3 receptor agonist. | Quinpirole|quinpirole|1H-Pyrazolo(3,4-g)quinoline, 4,4a,5,6,7,8,8a,9-octahydro-5-propyl-, (4aR-trans)-|QUINPIROLE | Quinpirole |
C0600427 | A psychologically and socially impaired state, with or without physiological changes, that develops as a result of using cocaine and which leads to compulsive behaviors to acquire the substance. | Cocaine dependence (disorder)|dependence cocaine|Cocaine Dependence|cocaine dependence|Cocaine dependence, unspecified|Addiction, Cocaine|addiction cocaine|Dependences, Cocaine|Cocaine Addiction|Cocaine dependence, unspecified use|Dependence, Cocaine|cocaine addiction|Cocaine dependence | Cocaine Dependence |
C0257694 | A protein kinase C subtype that was originally characterized as a CALCIUM-independent, serine-threonine kinase that is activated by PHORBOL ESTERS and DIACYLGLYCEROLS. It is targeted to specific cellular compartments in response to extracellular signals that activate G-PROTEIN-COUPLED RECEPTORS; TYROSINE KINASE RECEPTORS; and intracellular protein tyrosine kinase. | Kinase C-epsilon, Protein|Protein Kinase C epsilon|PKC-epsilon Serine Threonine Kinase|PKC epsilon Serine Threonine Kinase|PKC epsilon|Protein Kinase C-epsilon | Protein Kinase C-epsilon |
C0211726 | endogenous compound produced in the brain and possibly other organs, which binds to one of the most ubiquitous receptors in the brain, the delta9- tetrahydrocannabinol receptor. | arachidonylethanolamide|N-arachidonoyl-2-hydroxyethylamide|5,8,11,14-eicosatetraenamide, N-(2-hydroxyethyl)-|5,8,11,14-eicosatetraenoylethanolamide|arachidonoylethanolamide|anandamides|5,8,11,14-Eicosatetraenamide, N-(2-hydroxyethyl)-, (all-Z)-|arachidonoyl ethanolamide|N arachidonoyl 2 hydroxyethylamide|anandamide (20.4,n-6)|anandamide|N-(2-hydroxyethyl)arachidonamide | anandamide |
C1142933 | A pyrazole and piperidine derivative that acts as a selective cannabinoid type-1 receptor (CB1 RECEPTOR) antagonist. It inhibits the proliferation and maturation of ADIPOCYTES, improves lipid and glucose metabolism, and regulates food intake and energy balance. It is used in the management of OBESITY. | rimonabant|5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide|Rimonabant-containing product|Rimonabant|Product containing rimonabant (medicinal product)|1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-|RIMONABANT|Rimonabant (substance) | Rimonabant |
C0037316 | The state of being deprived of sleep under experimental conditions, due to life events, or from a wide variety of pathophysiologic causes such as medication effect, chronic illness, psychiatric illness, or sleep disorder. | Sleep deprivation|sleep deprivations|Lack of adequate sleep|sleep deprivation|Deprivations, Sleep|not enough sleeping|Sleep Deprivations|Sleep deprivation (finding)|Sleep Deprivation|Deprivation, Sleep | Sleep Deprivation |
C0035397 | An object or a situation that can serve to reinforce a response, to satisfy a motive, or to afford pleasure. | Reward (Psychology)|reward|Rewards|rewarding|rewards|Reward|reward (psychology) | Rewards |
C1266864 | null | eating habit|Eating habit|Eating habit (life style)|eating habits | Eating habit |
C0079294 | Form of epidermolysis bullosa characterized by atrophy of blistered areas, severe scarring, and nail changes. It is most often present at birth or in early infancy and occurs in both autosomal dominant and recessive forms. All forms of dystrophic epidermolysis bullosa result from mutations in COLLAGEN TYPE VII, a major component fibrils of BASEMENT MEMBRANE and EPIDERMIS. | Dystrophica, Epidermolysis Bullosa|Epidermolysis Bullosa Dystrophica|bullosa dystrophic epidermolysis|bullosa dystrophica epidermolysis|Bullosa Dystrophica, Epidermolysis|Dystrophic Epidermolysis Bullosa|Bullosa, Dystrophic Epidermolysis|Epidermolysis Bullosas, Dystrophic|Epidermolysis Bullosa, Dystrophic|DEB - Dystrophic epidermolysis bullosa|epidermolysis bullosa dystrophic|Bullosa Dystrophicas, Epidermolysis|Epidermolysis bullosa, dystrophic|dystrophic epidermolysis bullosa|Dystrophicas, Epidermolysis Bullosa|Epidermolysis bullosa dystrophica|Dystrophic epidermolysis bullosa|Epidermolysis Bullosa Dystrophicas|Bullosas, Dystrophic Epidermolysis|Dystrophic Epidermolysis Bullosas|Dystrophic epidermolysis bullosa (disorder) | Epidermolysis Bullosa Dystrophica |
C0524914 | Cell surface glycoproteins that bind to chemokines and thus mediate the migration of pro-inflammatory molecules. The receptors are members of the seven-transmembrane G protein-coupled receptor family. Like the CHEMOKINES themselves, the receptors can be divided into at least three structural branches: CR, CCR, and CXCR, according to variations in a shared cysteine motif. | Chemokine Receptor|chemokine receptor|chemokine receptors|Receptors, Chemokine|Chemokine Receptors | chemokine receptor |
C0003864 | Acute or chronic inflammation of JOINTS. | Inflammation of joint NOS|Inflammatory arthritis|Arthritides|INFLAMMATORY ARTHROPATHIES|joint inflammation|Arthritis, inflammatory|Joint inflamed|Arthritis (disorder)|arthritis|Joint inflammation|arthritide|ARTHRITIS|Arthritis|arthritides|inflammatory arthritis|Inflammatory arthropathy|JOINT INFLAMMATION|Arthritis, NOS | Arthritis |
C1413966 | null | DEAH BOX POLYPEPTIDE 9|DHX9 gene|leukophysin|nuclear DNA helicase II|DDX9|RNA HELICASE A|RNA helicase A|DExH-box helicase 9|NDHII|RHA|DHX9|NDH II|NUCLEAR DNA HELICASE II|DEAD/H BOX 9 | DHX9 gene |
C1413966 | null | DEAH BOX POLYPEPTIDE 9|DHX9 gene|leukophysin|nuclear DNA helicase II|DDX9|RNA HELICASE A|RNA helicase A|DExH-box helicase 9|NDHII|RHA|DHX9|NDH II|NUCLEAR DNA HELICASE II|DEAD/H BOX 9 | DHX9 gene |
C0151306 | null | null | Muscle weakness: extension of knee, dorsiflexion and inversion of foot |
C0070976 | null | null | phthiocerol dimycocerosate |
C0598099 | An envelope that surrounds a bacterial cell and includes the cytoplasmic membrane and everything external, encompassing the periplasmic space, cell wall, and outer membrane if present. [GOC:ds, GOC:mlg, http://pathmicro.med.sc.edu/fox/cell_envelope.htm] | cell envelope | cell envelope |
C0051981 | <p>leprosy vaccine</p> | anti-leprosy vaccine|Leprosy|antileprosy vaccine|leprosy vaccine|leprosy | leprosy vaccine |
C0051981 | <p>leprosy vaccine</p> | anti-leprosy vaccine|Leprosy|antileprosy vaccine|leprosy vaccine|leprosy | leprosy vaccine |
C0021641 | A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). | Unmodified insulin preparation|regular insulin|Insulin|insulin|insulin regular|Product containing insulin (product)|insulin preparations|insulins|Regular Insulin|Regular insulin preparation|insulin products|Insulin, Soluble|insulin preparation|insulin product|INSULIN PREPARATIONS|Insulin (substance)|Insulin, Regular|Soluble Insulin|Insulin preparation, NOS|Insulin-containing product | Insulin |
C0752065 | A large family of MONOMERIC GTP-BINDING PROTEINS that play a key role in cellular secretory and endocytic pathways. | rab GTPases|rab GTP Binding Proteins|rab G Proteins|GTP-Binding Proteins, rab|G-Proteins, rab|rab G-Proteins|GTPases, rab | rab GTP-Binding Proteins |
C1414218 | null | RD|DYX1 gene|DYX1|dyslexia susceptibility 1 | DYX1 gene |
C1414218 | null | RD|DYX1 gene|DYX1|dyslexia susceptibility 1 | DYX1 gene |
C0008395 | Cholesterol present in food, especially in animal products. | dietary cholesterol|Dietary Cholesterol|cholesterol dietary | Cholesterol, Dietary |
C0008395 | Cholesterol present in food, especially in animal products. | dietary cholesterol|Dietary Cholesterol|cholesterol dietary | Cholesterol, Dietary |
C0018353 | Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety. | Triphosphate, Guanosine|Guanosine 5'-(Tetrahydrogen Triphosphate)|gtp|Guanosine triphosphate (GTP)|GTP|guanosine triphosphate (GTP)|Guanosine Triphosphate|Guanosine 5'-(tetrahydrogen triphosphate)|Guanosine triphosphate|Guanosine triphosphate (substance)|guanosine triphosphate | Guanosine Triphosphate |
C0887840 | The directed movement of substances out of the nucleus. [GOC:ai] | nucleus export|export from nucleus|nuclear export|substance nuclear export|Export, Nuclear | Nuclear Export |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.